The Invesco Pharmaceuticals ETF has delivered significantly higher 1-year total returns than the Simplify Health Care ETF.
The Simplify Health Care ETF operates with a lower expense ratio and follows a unique pro bono model that supports breast cancer research.
The Invesco Pharmaceuticals ETF maintains a concentrated portfolio of 30 pharmaceutical companies, while Simplify's fund provides broader healthcare sub-sector exposure.
Comparing the Simplify Health Care ETF (NYSEMKT:PINK) and Invesco Pharmaceuticals ETF (NYSEMKT:PJP) reveals distinct approaches to healthcare, with PINK focusing on broad innovation through active management and PJP offering concentrated exposure to the U.S. pharmaceutical industry.
Investors seeking healthcare exposure must often choose between the stability of established pharmaceutical giants and the growth potential of medical technology. The Simplify Health Care ETF uses an active strategy to find innovators, while the Invesco Pharmaceuticals ETF tracks a rules-based index of 30 specialized companies engaged in drug research and distribution.
| Metric | PJP | PINK |
|---|---|---|
| Issuer | Invesco | Simplify |
| Share price | $131.04 (as of 2026-11-13) | $39.98 (as of 2026-11-13) |
| Expense ratio | 0.58% | 0.51% |
| 1-yr return (as of Oct. 31, 2026) | 36.1% | 22.7% |
| Dividend yield | 0.9% | 0.8% |
| Beta | 0.32 | 0.69 |
| AUM | $581.9 million | $345.2 million |
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
The Simplify Health Care ETF is the more affordable option with a 0.51% expense ratio, compared to the 0.58% charged by the Invesco Pharmaceuticals ETF. The yield difference is marginal, as PJP offers a slightly higher trailing-12-month payout than PINK.
| Metric | PJP | PINK |
|---|---|---|
| Max drawdown (5 yr) | (17.5%) | (18.7%) |
| Growth of $1,000 over 5 years (total return) | $1,673 | $1,595 |
The Simplify Health Care ETF is an actively managed fund that targets long-term capital appreciation by investing in healthcare sub-sectors like gene therapy, medical technology, and biotechnology. Managed by Michael Taylor, it maintains 58 holdings and allocates about 91% of its portfolio to healthcare stocks, with small exposures to consumer cyclicals and industrials. Its largest positions include Eli Lilly and Co. (NYSE:LLY) at 8.15%, Humana (NYSE:HUM) at 8.08%, and Arcutis Biotherapeutics (NASDAQ:ARQT) at 6.60%. The fund was launched in 2021 and carries a currency hedge quirk. It has paid $0.30 per share over the trailing 12 months, which on its recent ~$39 share price works out to a 0.8% yield.
The Invesco Pharmaceuticals ETF focuses entirely on the U.S. pharmaceutical industry, providing concentrated exposure to companies involved in the research and manufacture of drugs. It currently holds 28 stocks and is classified as non-diversified. Its top holdings include AbbVie (NYSE:ABBV) at 5.87%, Gilead Sciences (NASDAQ:GILD) at 5.73%, and Pfizer (NYSE:PFE) at 5.58%. This fund was launched in 2005 and passively tracks a specific index rather than using active management. It has paid $1.13 per share over the trailing 12 months, which on its recent ~$123 share price works out to a 0.9% yield.
For more guidance on ETF investing, check out the full guide at this link.
Investors interested in healthcare exposure have very different choices in the Invesco Pharmaceuticals ETF (PJP) and Simplify Health Care ETF (PINK). For starters, the latter is actively-managed while PJP is a passive fund. Several additional factors may impact your decision to choose between these ETFs.
PINK donates its profits to the Susan G. Komen Foundation in the fight against breast cancer, so your investment contributes to this cause. It seeks to invest broadly across the healthcare sector without regard to company weightings in industry indices. Its expense ratio is lower, saving you money, and it is more diversified than PJP. However, its one-year and five-year returns are not as strong, and the fund has only existed since 2021, providing limited visibility into its performance over various macroeconomic cycles.
PJP seeks to replicate the performance of the Dynamic Pharmaceutical Intellidex Index, so its holdings reflect that. It's been around since 2005, providing over 20 years of history to help you gauge long-term returns. It's the ideal fund if you want exposure to domestic drugmakers and major pharmaceutical catalysts such as the GLP-1 weight-loss drugs. Yet that same focus can be a drawback if the pharma industry experiences a downturn.
Before you buy stock in Simplify Exchange Traded Funds - Simplify Health Care ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Simplify Exchange Traded Funds - Simplify Health Care ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*
Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 15, 2026.
Robert Izquierdo has positions in Pfizer. The Motley Fool has positions in and recommends AbbVie, Eli Lilly, Gilead Sciences, and Pfizer. The Motley Fool has a disclosure policy.